@NP	Functional Repair of Rat Corticospinal Tract Lesions	1
@NP	Functional Repair	1
@NP	Rat Corticospinal Tract Lesions	22
@NP	Permanent Survival of an Immunoincompatible Transplant Ying Li , Daqing Li	71
@NP	Permanent Survival	71
@NP	an Immunoincompatible Transplant Ying Li , Daqing Li	93
@NP	Geoffrey Raisman Cell transplantation	151
@NP	Geoffrey Raisman	151
@NP	Cell transplantation	169
@NP	one of the most promising strategies for repair of human spinal cord injuries	193
@NP	one	193
@NP	the most promising strategies for repair of human spinal cord injuries	200
@NP	the most promising strategies	200
@NP	repair of human spinal cord injuries	234
@NP	repair	234
@NP	human spinal cord injuries	244
@NP	Animal studies from a number of laboratories	272
@NP	Animal studies	272
@NP	a number of laboratories	292
@NP	a number	292
@NP	laboratories	304
@NP	transplantation	333
@NP	olfactory ensheathing cells cultured from biopsies of the olfactory bulb	352
@NP	olfactory ensheathing cells	352
@NP	biopsies of the olfactory bulb	394
@NP	biopsies	394
@NP	the olfactory bulb	406
@NP	axonal regeneration and remyelination	433
@NP	lost functions in spinal cord injuries	483
@NP	lost functions	483
@NP	spinal cord injuries	501
@NP	translation	527
@NP	small laboratory experimental injuries	544
@NP	the large spinal cord injuries encountered in human patients	586
@NP	the large spinal cord injuries	586
@NP	human patients	632
@NP	the numbers of cells that can be obtained from a patient 's own olfactory bulb	647
@NP	the numbers	647
@NP	cells that can be obtained from a patient 's own olfactory bulb	662
@NP	cells	662
@NP	a patient 's own olfactory bulb	694
@NP	a patient 's	694
@NP	a serious	733
@NP	factor	752
@NP	removal of an olfactory bulb	773
@NP	removal	773
@NP	an olfactory bulb	784
@NP	invasive surgery and risks unilateral anosmia	811
@NP	invasive surgery	811
@NP	risks unilateral anosmia	832
@NP	risks	832
@NP	unilateral anosmia	838
@NP	We	858
@NP	xenografted mouse bulbar olfactory ensheathing cells	878
@NP	daily cyclosporine	950
@NP	forepaw	986
@NP	function	1003
@NP	rats with chronic C1/2 unilateral corticospinal tract lesions	1015
@NP	rats	1015
@NP	chronic C1/2 unilateral corticospinal tract lesions	1025
@NP	chronic C1/2	1025
@NP	unilateral corticospinal tract lesions	1038
@NP	function	1083
@NP	10 days	1117
@NP	cyclosporine	1126
@NP	Thirteen out of 13 rats	1154
@NP	Thirteen	1154
@NP	13 rats	1170
@NP	forepaw reaching	1209
@NP	forepaw	1209
@NP	Immunohistochemistry	1227
@NP	all cases	1262
@NP	neurofilamentpositive axons	1272
@NP	the lesion	1316
@NP	the grafted cells	1337
@NP	This	1382
@NP	cells	1413
@NP	bridges for axon regeneration	1433
@NP	bridges	1433
@NP	axon regeneration	1445
@NP	the lesion site	1470
@NP	their continued presence	1486
@NP	the restored function	1550
@NP	This	1573
@NP	the possibility	1585
@NP	the future	1609
@NP	a protocol of temporary immunoprotection	1620
@NP	a protocol	1620
@NP	temporary immunoprotection	1634
@NP	the use	1677
@NP	the larger available numbers	1688
@NP	immunoincompatible allografted cells or cell lines	1720
@NP	immunoincompatible allografted cells	1720
@NP	cell lines	1760
@NP	the need	1790
@NP	a patient 's olfactory bulb	1812
@NP	a patient 's	1812
@NP	INTRODUCTION A number of studies	1841
@NP	INTRODUCTION A number	1841
@NP	studies	1866
@NP	transplanted olfactory ensheathing cells -LRB- OECs -RRB-	1890
@NP	transplanted olfactory ensheathing cells	1890
@NP	OECs	1932
@NP	axon regeneration , remyelination , and restoration of function	1949
@NP	axon regeneration	1949
@NP	remyelination	1968
@NP	restoration of function	1987
@NP	restoration	1987
@NP	function	2002
@NP	experimental spinal cord injuries -LRB- 7,8,10,15,21,22,27,28 -RRB-	2014
@NP	experimental spinal cord injuries	2014
@NP	7,8,10,15,21,22,27,28	2049
@NP	We	2073
@NP	a localized stereotaxic heat lesion	2091
@NP	the adult rat corticospinal tract	2149
@NP	CST	2184
@NP	partial adjacent medial gray matter	2193
@NP	the C1/2 level	2245
@NP	this lesion	2271
@NP	forepaw reaching -LRB- DFR -RRB- on the lesion side	2293
@NP	forepaw	2293
@NP	-LRB- DFR -RRB- on the lesion side	2310
@NP	-LRB- DFR -RRB-	2310
@NP	the lesion side	2319
@NP	2 months after lesion	2358
@NP	2 months	2358
@NP	lesion	2373
@NP	injection	2381
@NP	a suspension	2394
@NP	a mixture	2410
@NP	adult bulbar OECs and olfactory nerve fibroblasts -LRB- ONFs -RRB-	2432
@NP	adult bulbar OECs	2432
@NP	olfactory nerve fibroblasts -LRB- ONFs -RRB-	2454
@NP	olfactory nerve fibroblasts	2454
@NP	ONFs	2483
@NP	DFR	2498
@NP	around 10 days -LRB- 12 -RRB-	2508
@NP	around 10 days	2508
@NP	12	2524
@NP	translation to clinical application	2533
@NP	translation	2533
@NP	clinical application	2548
@NP	removal of a patient 's olfactory bulb	2570
@NP	removal	2570
@NP	a patient 's olfactory bulb	2581
@NP	a patient 's	2581
@NP	a transdural endoscopic or intracranial approach	2621
@NP	the risk of unilateral anosmia	2676
@NP	the risk	2676
@NP	unilateral anosmia	2688
@NP	One way to obtain more cells and to avoid the problems of autograft biopsy	2708
@NP	One way	2708
@NP	more cells	2726
@NP	the problems of autograft biopsy	2750
@NP	the problems	2750
@NP	autograft biopsy	2766
@NP	a bank of allogeneic cells or cell lines -LRB- 16 -RRB-	2804
@NP	a bank	2804
@NP	allogeneic cells or cell lines -LRB- 16 -RRB-	2814
@NP	allogeneic cells or cell lines	2814
@NP	16	2846
@NP	transplants	2854
@NP	these	2867
@NP	an immune barrier	2903
@NP	A number of studies with immunoincompatible grafts	2922
@NP	A number	2922
@NP	studies with immunoincompatible grafts	2934
@NP	studies	2934
@NP	immunoincompatible grafts	2947
@NP	xenografted OECs immunoprotected with cyclosporine	2989
@NP	xenografted OECs	2989
@NP	cyclosporine	3027
@NP	axon regeneration and remyelination	3047
@NP	the spinal cord -LRB- 10,11,18,19,29 -RRB-	3086
@NP	the spinal cord	3086
@NP	10,11,18,19,29	3103
@NP	permanent immunosuppression	3132
@NP	many disadvantages	3168
@NP	the present experiment	3191
@NP	we	3214
@NP	a mouse	3222
@NP	rat xenograft paradigm	3233
@NP	functions restored under transient immunosuppression	3272
@NP	functions	3272
@NP	transient immunosuppression	3297
@NP	the immunosuppressive regime	3344
@NP	MATERIAL AND METHODS Experimental Design A total of 58	3392
@NP	MATERIAL AND METHODS	3392
@NP	Experimental Design	3413
@NP	A total of 58	3433
@NP	A total	3433
@NP	58	3444
@NP	strain	3466
@NP	adult female Albino Swiss rats	3476
@NP	London , UK , body weight 200 -- 220 g	3522
@NP	London , UK , body weight 200	3522
@NP	London , UK	3522
@NP	body weight 200	3534
@NP	body weight	3534
@NP	200	3546
@NP	220 g	3550
@NP	Group 1	3568
@NP	Twenty unlesioned rats	3577
@NP	mouse OEC	3609
@NP	mouse	3609
@NP	OEC	3615
@NP	ONF xenografts without immunosuppression	3620
@NP	ONF xenografts	3620
@NP	immunosuppression	3643
@NP	Histology	3662
@NP	4 days -LRB- n = 5 -RRB-	3691
@NP	n	3699
@NP	5	3703
@NP	1 -LRB- n = 5 -RRB-	3707
@NP	1	3707
@NP	n	3710
@NP	5	3714
@NP	2 -LRB- n = 4 -RRB-	3718
@NP	2	3718
@NP	n	3721
@NP	4	3725
@NP	3 -LRB- n = 3 -RRB-	3729
@NP	3	3729
@NP	n	3732
@NP	3	3736
@NP	4 weeks -LRB- n = 3 -RRB-	3744
@NP	n	3753
@NP	3	3757
@NP	The remaining 38 rats	3761
@NP	CST lesions	3787
@NP	DFR	3819
@NP	Group 2	3824
@NP	11/38 of these rats	3836
@NP	11/38	3836
@NP	these rats	3845
@NP	DFR	3856
@NP	they	3888
@NP	histology	3913
@NP	Group 3	3924
@NP	8/38 rats in which DFR was abolished	3936
@NP	8/38 rats	3936
@NP	DFR	3955
@NP	they	3974
@NP	10	3993
@NP	12 months	3996
@NP	a long-term control	4010
@NP	DFR	4044
@NP	sacrifice and histology	4073
@NP	The remaining 19/38 rats	4098
@NP	mouse OEC/ONF xenografts	4136
@NP	8 weeks	4164
@NP	the CST lesions	4178
@NP	Cyclosporine administration	4195
@NP	daily injections	4276
@NP	Group 4	4294
@NP	6/19 rats	4306
@NP	no return of DFR at 5 weeks	4328
@NP	no return	4328
@NP	DFR at 5 weeks	4341
@NP	DFR	4341
@NP	5 weeks	4348
@NP	mouse OEC transplants	4372
@NP	they	4395
@NP	histology	4420
@NP	Group 5	4431
@NP	the remaining 13/19 rats	4443
@NP	DFR	4474
@NP	mouse OEC transplants	4507
@NP	cyclosporine injection	4530
@NP	a further 10 days	4571
@NP	the day when DFR had returned	4595
@NP	the day	4595
@NP	DFR	4608
@NP	Ten days later	4626
@NP	cyclosporine	4642
@NP	DFR testing	4672
@NP	two to three times a week	4698
@NP	two to three times	4698
@NP	a week	4717
@NP	8 weeks	4730
@NP	the transplants	4754
@NP	Directed Forepaw Reaching -LRB- DFR -RRB- and Microsurgery All animals	4771
@NP	Directed Forepaw	4771
@NP	-LRB- DFR -RRB- and Microsurgery All animals	4797
@NP	-LRB- DFR -RRB-	4797
@NP	Microsurgery All animals	4807
@NP	the UK Home Office regulations ASPA 5 -LRB- 2 -RRB-	4858
@NP	the UK Home Office regulations	4858
@NP	ASPA 5 -LRB- 2 -RRB-	4889
@NP	ASPA 5	4889
@NP	2	4896
@NP	PIL 70/9580 for the care	4899
@NP	PIL 70/9580	4899
@NP	the care	4915
@NP	use	4928
@NP	laboratory animals	4935
@NP	the UK Animals	4955
@NP	Scientific Procedures	4971
@NP	Act 1986 with the ethical approval of the UCL Institute for Neurology	4994
@NP	Act 1986	4994
@NP	the ethical approval of the UCL Institute for Neurology	5008
@NP	the ethical approval	5008
@NP	the UCL Institute for Neurology	5032
@NP	the UCL Institute	5032
@NP	Neurology	5054
@NP	Presurgery	5065
@NP	DFR	5077
@NP	as previously described -LRB- 12 -RRB-	5097
@NP	as previously	5097
@NP	12	5122
@NP	the rats	5135
@NP	the forepaws	5164
@NP	small pieces of noodles	5189
@NP	small pieces	5189
@NP	noodles	5205
@NP	a slit in the front of the cage	5221
@NP	a slit	5221
@NP	the front of the cage	5231
@NP	the front	5231
@NP	the cage	5244
@NP	50 retrievals each session	5259
@NP	50 retrievals	5259
@NP	each session	5273
@NP	Rats that used both right and left paws -LRB- more than 15 times each -RRB-	5287
@NP	Rats	5287
@NP	both right	5302
@NP	paws -LRB- more than 15 times each -RRB-	5322
@NP	paws	5322
@NP	15 times each	5338
@NP	15 times	5338
@NP	each	5347
@NP	the CST lesions	5378
@NP	CST Lesions .	5395
@NP	CST	5395
@NP	Lesions	5399
@NP	Rats	5408
@NP	isoflurane	5436
@NP	Abbott	5448
@NP	Laboratories Ltd. , Maidenhead , and Berkshire , UK	5455
@NP	Laboratories Ltd.	5455
@NP	Maidenhead	5474
@NP	Berkshire , UK	5490
@NP	Unilateral CST lesions	5506
@NP	C1 and C2 vertebrae	5547
@NP	an electrode -LRB- LCE ; Cosman Medical Inc. , Burlington , MA , USA -RRB-	5574
@NP	an electrode	5574
@NP	LCE ; Cosman Medical Inc. , Burlington , MA , USA	5588
@NP	LCE	5588
@NP	Cosman Medical Inc. , Burlington , MA , USA	5593
@NP	The CST and adjacent gray matter	5636
@NP	The CST	5636
@NP	adjacent gray matter	5648
@NP	a heat lesion	5687
@NP	a radiofrequency lesion device	5713
@NP	RFG-3C RF ; Radionics Inc. , Burlington , MA , USA	5745
@NP	RFG-3C RF	5745
@NP	Radionics Inc. , Burlington , MA , USA	5756
@NP	10 V for 1 min as previously described -LRB- 32 -RRB-	5806
@NP	10 V	5806
@NP	1 min as previously described -LRB- 32 -RRB-	5815
@NP	1 min	5815
@NP	32	5846
@NP	Postsurgery	5851
@NP	DFR testing	5864
@NP	3 days	5888
@NP	the lesion , two to three times a week	5901
@NP	the lesion	5901
@NP	two to three times a week	5913
@NP	two to three times	5913
@NP	a week	5932
@NP	Rats that showed complete absence of DFR for 8 weeks	5940
@NP	Rats	5940
@NP	complete absence of DFR	5957
@NP	complete absence	5957
@NP	DFR	5977
@NP	8 weeks	5985
@NP	mouse OEC transplants -LRB- Groups 4 and 5 -RRB-	6018
@NP	mouse OEC transplants	6018
@NP	Groups 4 and 5	6041
@NP	Groups 4	6041
@NP	5	6054
@NP	Eight rats with complete absence of DFR	6058
@NP	Eight rats	6058
@NP	complete absence of DFR	6074
@NP	complete absence	6074
@NP	DFR	6094
@NP	12 months as a long-term control -LRB- Group 3 -RRB-	6120
@NP	12 months	6120
@NP	a long-term control -LRB- Group 3 -RRB-	6133
@NP	a long-term control	6133
@NP	Group 3	6154
@NP	OEC Culture	6164
@NP	The tissue from the outer nerve	6176
@NP	The tissue	6176
@NP	the outer nerve	6192
@NP	glomerular layers	6212
@NP	the olfactory bulbs of -LRB- n = 40 -RRB- 5-month-old female C57BL/6	6233
@NP	the olfactory bulbs	6233
@NP	n = 40	6257
@NP	n	6257
@NP	= 40	6259
@NP	5-month-old female C57BL/6	6265
@NP	Harlan Laboratories	6293
@NP	Bicester	6314
@NP	Oxfordshire , UK	6324
@NP	0.1 % ; Worthington Biochemical Corporation , Lakewood , NJ , USA	6358
@NP	0.1 %	6358
@NP	Worthington Biochemical Corporation , Lakewood , NJ , USA	6364
@NP	Worthington	6364
@NP	Biochemical	6376
@NP	Corporation , Lakewood , NJ , USA	6388
@NP	15 min	6424
@NP	37 °C	6434
@NP	35-mm Nunc ™ dishes	6456
@NP	Thermo Fisher Scientific UK	6476
@NP	Hertfordshire	6505
@NP	UK	6520
@NP	poly-d-lysine -LRB- Sigma - Aldrich , Dorset , UK -RRB-	6536
@NP	poly-d-lysine	6536
@NP	Sigma	6551
@NP	Aldrich , Dorset , UK	6558
@NP	Aldrich	6558
@NP	Dorset , UK	6567
@NP	The cells	6580
@NP	15	6610
@NP	16 days in DMEM-F12 -LRB- Life Technologies Ltd , Paisley , UK -RRB- medium	6613
@NP	16 days	6613
@NP	DMEM-F12 -LRB- Life Technologies Ltd , Paisley , UK -RRB- medium	6624
@NP	DMEM-F12 -LRB- Life Technologies Ltd , Paisley , UK -RRB-	6624
@NP	DMEM-F12	6624
@NP	Life Technologies Ltd , Paisley , UK	6634
@NP	Life Technologies Ltd	6634
@NP	Paisley , UK	6657
@NP	10 % fetal calf serum	6692
@NP	3133-028 ; Gibco , Paisley , UK	6714
@NP	3133-028	6714
@NP	Gibco , Paisley , UK	6724
@NP	The OECs	6745
@NP	p75 immunostaining	6773
@NP	anti-nerve growth factor receptor antibody	6793
@NP	extracellular	6837
@NP	clone 192-IgG -LRB- MAB365 -RRB-	6852
@NP	clone 192-IgG	6852
@NP	MAB365	6867
@NP	Millipore Ltd Hertfordshire	6876
@NP	UK -RSB-	6905
@NP	the ONFs	6914
@NP	FN	6939
@NP	polyclonal rabbit	6959
@NP	A0245 ; Dako Ltd , Cambridgeshire , UK	7001
@NP	A0245	7001
@NP	Dako Ltd , Cambridgeshire , UK	7008
@NP	Transplantation Two days before transplantation	7040
@NP	Transplantation	7040
@NP	Two days	7056
@NP	transplantation	7072
@NP	the cells were transfected with a GFP gene harboring lentiviral construct	7088
@NP	the cells	7088
@NP	a GFP gene	7120
@NP	lentiviral construct	7141
@NP	4,17,24	7163
@NP	The cell suspension	7173
@NP	a final concentration of 25 × 106/ml in DMEM-F12	7208
@NP	a final concentration	7208
@NP	25 × 106/ml in DMEM-F12	7233
@NP	25 × 106/ml	7233
@NP	DMEM-F12	7248
@NP	FCS	7265
@NP	Four microliters of the suspension -LRB- around 100,000 cells -RRB-	7270
@NP	Four microliters	7270
@NP	the suspension -LRB- around 100,000 cells -RRB-	7290
@NP	the suspension	7290
@NP	100,000 cells	7313
@NP	the lesion site via a glass micropipette	7347
@NP	the lesion site	7347
@NP	a glass micropipette	7367
@NP	a 100	7393
@NP	120-μm internal tip diameter	7403
@NP	transplantation	7451
@NP	cyclosporine -LRB- Novartis , Surrey , UK -RRB-	7468
@NP	cyclosporine	7468
@NP	Novartis	7482
@NP	Surrey	7492
@NP	UK	7500
@NP	15 mg/ml	7515
@NP	20 % Tween	7527
@NP	80 solution -LRB- Sigma - Aldrich -RRB-	7537
@NP	Sigma - Aldrich	7550
@NP	Sigma	7550
@NP	Aldrich	7557
@NP	a dosage	7569
@NP	6 mg/kg with 100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB-	7581
@NP	6 mg/kg	7581
@NP	100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB-	7594
@NP	100 % ethanol	7594
@NP	VWR	7608
@NP	Fontenay Sous Bois	7613
@NP	France	7633
@NP	IP	7674
@NP	Microfine insulin syringes -LRB- BD Ltd , Dun Laoghaire , Ireland -RRB-	7682
@NP	Microfine insulin syringes	7682
@NP	BD Ltd , Dun Laoghaire , Ireland	7710
@NP	BD Ltd	7710
@NP	Dun Laoghaire	7718
@NP	Ireland	7733
@NP	DFR testing	7762
@NP	3 days	7788
@NP	the transplantation	7801
@NP	two to three times weekly	7836
@NP	Immunohistochemistry Rats	7863
@NP	4 % paraformaldehyde -LRB- TAAB Laboratories Equipment Ltd , Reading , UK -RRB-	7908
@NP	4 % paraformaldehyde	7908
@NP	TAAB	7929
@NP	Laboratories Equipment Ltd , Reading , UK	7934
@NP	Laboratories Equipment Ltd	7934
@NP	Reading , UK	7962
@NP	terminal anesthesia -LSB- for details	7981
@NP	terminal anesthesia -LSB-	7981
@NP	details	8006
@NP	Keyvan-Fouladi	8019
@NP	et al. -LRB- 12 -RRB-	8034
@NP	et al.	8034
@NP	12	8042
@NP	Coronal or horizontal cryostat sections , 16 μm ,	8048
@NP	Coronal or horizontal cryostat sections	8048
@NP	Coronal	8048
@NP	horizontal cryostat sections	8059
@NP	16 μm	8089
@NP	GFP/NF	8127
@NP	neurofilament	8135
@NP	rabbit anti-H	8150
@NP	L chain NF 1:500 ; Invitrogen , Paisley , UK -RRB-	8164
@NP	L chain NF	8164
@NP	1:500 ; Invitrogen , Paisley , UK -RRB-	8175
@NP	1:500	8175
@NP	Invitrogen , Paisley , UK	8182
@NP	Invitrogen	8182
@NP	Paisley , UK	8194
@NP	glial fibrillary acidic protein -LRB- GFAP/NF -RRB-	8208
@NP	glial fibrillary acidic protein	8208
@NP	GFAP/NF	8241
@NP	mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen	8251
@NP	mouse	8251
@NP	anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen	8257
@NP	anti-GFAP 1:1,000 , rabbit anti-H	8257
@NP	anti-GFAP 1:1,000	8257
@NP	rabbit anti-H	8276
@NP	L chain NF 1:500 ; Invitrogen	8290
@NP	L chain NF 1:500	8290
@NP	L chain NF	8290
@NP	1:500	8301
@NP	Invitrogen	8308
@NP	CD45 -LRB- mouse anti-CD45 1:500	8321
@NP	CD45	8321
@NP	mouse anti-CD45 1:500	8327
@NP	mouse	8327
@NP	1:500	8343
@NP	BD Pharmingen , Oxford	8350
@NP	BD Pharmingen	8350
@NP	Oxford	8365
@NP	UK	8373
@NP	The sections	8378
@NP	Alexa Fluor	8418
@NP	488	8430
@NP	goat anti-rabbit , anti-mouse , or goat anti-chicken	8454
@NP	goat anti-rabbit	8454
@NP	1:400 ; Invitrogen	8527
@NP	1:400	8527
@NP	Invitrogen	8534
@NP	2 h at room temperature	8550
@NP	2 h	8550
@NP	room temperature	8557
@NP	Sytox Orange , 0.1 μM -LRB- Life Technologies Ltd -RRB-	8575
@NP	Sytox Orange	8575
@NP	0.1 μM -LRB- Life Technologies Ltd -RRB-	8589
@NP	0.1 μM	8589
@NP	Life Technologies Ltd	8597
@NP	cell counterstaining	8633
@NP	Fluorescent images	8655
@NP	a Leica	8694
@NP	confocal microscope TCS SP -LRB- Milton Keynes , UK -RRB-	8702
@NP	confocal microscope TCS SP	8702
@NP	Milton Keynes	8730
@NP	UK	8745
@NP	RESULTS Figure 1 .	8751
@NP	RESULTS	8751
@NP	Figure 1	8759
@NP	Lesions and transplanted OECs .	8769
@NP	Lesions and transplanted OECs	8769
@NP	Lesions	8769
@NP	transplanted OECs	8781
@NP	-LRB- A , B , C -RRB-	8800
@NP	A , B , C	8801
@NP	1	8816
@NP	Mouse OECs	8819
@NP	rat CST , no cyclosporine , survival time , 4 days in -LRB- A -RRB- , 1 week	8848
@NP	rat CST	8848
@NP	no cyclosporine	8857
@NP	survival time	8874
@NP	4 days in -LRB- A -RRB- , 1 week	8889
@NP	4 days	8889
@NP	-LRB- A -RRB- , 1 week	8899
@NP	-LRB- A -RRB-	8899
@NP	1 week	8904
@NP	-LRB- B -RRB- , and 3 weeks	8914
@NP	-LRB- B -RRB-	8914
@NP	3 weeks	8923
@NP	C	8935
@NP	GFP labeling , green ; Sytox Orange nuclear counterstaining , red .	8939
@NP	GFP labeling , green	8939
@NP	GFP labeling	8939
@NP	green	8953
@NP	Sytox Orange nuclear counterstaining , red	8960
@NP	Sytox Orange nuclear counterstaining	8960
@NP	red	8998
@NP	-LRB- D -RRB- Group 4 .	9003
@NP	-LRB- D -RRB-	9003
@NP	Group 4	9007
@NP	restoration of DFR , the OECs	9023
@NP	restoration	9023
@NP	DFR , the OECs	9038
@NP	DFR	9038
@NP	the OECs	9043
@NP	the lesion	9067
@NP	GFP labeling , green ; GFAP immunostaining , red .	9079
@NP	GFP labeling , green	9079
@NP	GFP labeling	9079
@NP	green	9093
@NP	GFAP immunostaining , red	9100
@NP	GFAP immunostaining	9100
@NP	red	9121
@NP	Survival time	9126
@NP	8 weeks after CST lesion , 5 weeks after the transplantation	9151
@NP	8 weeks	9151
@NP	CST lesion , 5 weeks after the transplantation	9165
@NP	CST lesion	9165
@NP	5 weeks after the transplantation	9177
@NP	5 weeks	9177
@NP	the transplantation	9191
@NP	daily cyclosporine injection	9217
@NP	-LRB- E , F -RRB-	9247
@NP	E , F	9248
@NP	E	9248
@NP	F	9251
@NP	3	9260
@NP	Long-term complete lesions showing no recovery of DFR .	9263
@NP	Long-term complete lesions	9263
@NP	no recovery of DFR	9298
@NP	no recovery	9298
@NP	DFR	9313
@NP	NF/GFAP double immunostaining .	9318
@NP	NF/GFAP	9318
@NP	double immunostaining	9326
@NP	NF , red ; GFAP , green .	9349
@NP	NF , red	9349
@NP	NF	9349
@NP	red	9353
@NP	GFAP , green	9358
@NP	GFAP	9358
@NP	green	9364
@NP	Survival time , 10 months .	9371
@NP	Survival time	9371
@NP	10 months	9386
@NP	-LRB- F -RRB- High power .	9397
@NP	-LRB- F -RRB-	9397
@NP	High power	9401
@NP	G	9414
@NP	J -RRB- Group 5	9416
@NP	J	9416
@NP	Group 5	9419
@NP	Restoration of DFR after withdrawal temporary immunoprotection .	9428
@NP	Restoration	9428
@NP	DFR	9443
@NP	withdrawal temporary immunoprotection	9453
@NP	Complete destruction of the	9492
@NP	Complete destruction	9492
@NP	the	9516
@NP	cells	9532
@NP	NF/GFAP double staining .	9539
@NP	NF/GFAP	9539
@NP	double staining	9547
@NP	NF , red ; GFAP , green .	9564
@NP	NF , red	9564
@NP	NF	9564
@NP	red	9568
@NP	GFAP , green	9573
@NP	GFAP	9573
@NP	green	9579
@NP	Survival time	9586
@NP	16 weeks	9601
@NP	8 weeks after CST lesion , 8 weeks after the transplantation	9611
@NP	8 weeks	9611
@NP	CST lesion , 8 weeks after the transplantation	9625
@NP	CST lesion	9625
@NP	8 weeks after the transplantation	9637
@NP	8 weeks	9637
@NP	the transplantation	9651
@NP	-LRB- H -RRB- High power .	9673
@NP	-LRB- H -RRB-	9673
@NP	High power	9677
@NP	A -- C , I , J -RRB- Horizontal sections ; -LRB- D -- H -RRB-	9690
@NP	A -- C , I , J -RRB- Horizontal sections ;	9690
@NP	C , I , J -RRB- Horizontal	9692
@NP	C , I , J -RRB-	9692
@NP	C	9692
@NP	I	9695
@NP	J	9698
@NP	sections	9712
@NP	D -- H	9723
@NP	D	9723
@NP	H	9725
@NP	sections	9734
@NP	Scale bars	9744
@NP	100 μm -LRB- A , B , D -RRB-	9756
@NP	A , B , D	9764
@NP	50 μm -LRB- C , F , H , J -RRB-	9774
@NP	200 μm -LRB- E , G , I -RRB-	9794
@NP	E	9802
@NP	G	9805
@NP	I	9808
@NP	Figure 2 .	9813
@NP	Figure	9813
@NP	2	9820
@NP	function	9834
@NP	rejection of xenografts	9849
@NP	rejection	9849
@NP	xenografts	9862
@NP	Number	9874
@NP	forepaw reaches	9893
@NP	DFR	9910
@NP	± SD	9930
@NP	the 13 rats	9939
@NP	Group 5	9954
@NP	complete absence of DFR for 8 weeks	9973
@NP	complete absence	9973
@NP	DFR for 8 weeks	9993
@NP	DFR	9993
@NP	8 weeks	10001
@NP	an ipsilateral corticospinal tract lesion -LRB- Les -RRB-	10015
@NP	an ipsilateral corticospinal tract lesion	10015
@NP	Les	10058
@NP	return of DFR	10067
@NP	return	10067
@NP	DFR	10077
@NP	mouse OEC/ONF xenografts -LRB- TR -RRB-	10087
@NP	mouse OEC/ONF xenografts	10087
@NP	TR	10113
@NP	daily cyclosporine	10140
@NP	DFR	10160
@NP	all rats	10189
@NP	withdrawal of cyclosporine -LRB- CS/wd -RRB- at 10 days	10204
@NP	withdrawal	10204
@NP	cyclosporine -LRB- CS/wd -RRB- at 10 days	10218
@NP	cyclosporine -LRB- CS/wd -RRB-	10218
@NP	cyclosporine	10218
@NP	CS/wd	10232
@NP	10 days	10242
@NP	the first return of DFR	10256
@NP	the first return	10256
@NP	DFR	10276
@NP	Time scale , abscissa in weeks .	10281
@NP	Time scale	10281
@NP	abscissa in weeks	10293
@NP	abscissa	10293
@NP	weeks	10305
@NP	Group 1	10313
@NP	n	10322
@NP	20	10326
@NP	Nonlesioned Rats	10331
@NP	Mouse OEC/ONF Xenografts Without Immune Protection After 15	10358
@NP	Mouse OEC/ONF Xenografts	10358
@NP	Immune Protection	10391
@NP	15	10415
@NP	16 days in culture the biopsied mouse olfactory bulbs yielded a mixture of 60	10418
@NP	16 days	10418
@NP	culture the biopsied mouse olfactory bulbs yielded a mixture of 60	10429
@NP	culture the	10429
@NP	mouse olfactory bulbs yielded a mixture of 60	10450
@NP	mouse	10450
@NP	olfactory bulbs	10456
@NP	a mixture of 60	10480
@NP	a mixture	10480
@NP	60	10493
@NP	70 % p75 + spindle	10496
@NP	70 % p75	10496
@NP	spindle	10505
@NP	shaped bipolar or tripolar OECs	10514
@NP	30 -- 40 % FN	10550
@NP	30	10550
@NP	40 % FN	10553
@NP	short-processed multipolar ONFs	10572
@NP	This mixture	10605
@NP	the same C1/2 position in intact CST	10640
@NP	the same C1/2 position	10640
@NP	intact CST	10666
@NP	that where the lesions were carried out in the other groups	10680
@NP	that	10680
@NP	the lesions	10691
@NP	the other groups	10723
@NP	4 days	10744
@NP	the transplanted cells , identified by the GFP labeling ,	10751
@NP	the transplanted cells	10751
@NP	the GFP labeling	10789
@NP	The transplant area	10822
@NP	a compact ovoid hypercellular mass	10858
@NP	1 mm along the rostrocaudal axis of the host CST	10899
@NP	1 mm	10899
@NP	the rostrocaudal axis of the host CST	10910
@NP	the rostrocaudal axis	10910
@NP	the host CST	10935
@NP	0.3 mm	10959
@NP	the transplant	10979
@NP	the cells	10994
@NP	around 100 μm	11022
@NP	the surrounding mechanical forces	11062
@NP	parallel	11116
@NP	the host CST -LRB- Fig. 1A -RRB-	11128
@NP	the host CST	11128
@NP	Fig. 1A	11142
@NP	1	11155
@NP	week	11157
@NP	the numbers of GFP-labeled cells	11162
@NP	the numbers	11162
@NP	GFP-labeled cells	11177
@NP	around 30 % of those seen at 4 days	11211
@NP	around 30 %	11211
@NP	those seen at 4 days	11225
@NP	those	11225
@NP	4 days	11239
@NP	The majority of cells	11247
@NP	The majority	11247
@NP	cells	11263
@NP	their	11278
@NP	longitudinal pattern	11294
@NP	irregular blob-like shapes -LRB- Fig. 1B -RRB-	11351
@NP	irregular blob-like shapes	11351
@NP	Fig. 1B	11379
@NP	The background	11389
@NP	hollow cuffed areas	11435
@NP	an influx of host immunocytes and perivascular cuffing	11466
@NP	an influx	11466
@NP	host immunocytes and perivascular cuffing	11479
@NP	host immunocytes	11479
@NP	perivascular cuffing	11500
@NP	2 , 3 , and 4 weeks	11525
@NP	2	11525
@NP	3	11528
@NP	4 weeks	11535
@NP	no GFP-labeled cells	11543
@NP	any part	11580
@NP	the transplanted area	11592
@NP	the hypercellularity and the hollow vascular areas -LRB- Fig. 1C -RRB-	11630
@NP	the hypercellularity	11630
@NP	the hollow vascular areas -LRB- Fig. 1C -RRB-	11655
@NP	the hollow vascular areas	11655
@NP	Fig. 1C	11682
@NP	2 weeks	11695
@NP	immunostaining of CD45 -LRB- leukocyte common antigen -RRB-	11703
@NP	immunostaining of CD45	11703
@NP	immunostaining	11703
@NP	CD45	11721
@NP	leukocyte common antigen	11727
@NP	leukocyte	11727
@NP	common antigen	11737
@NP	cells intimately associated with the vessel walls	11760
@NP	cells	11760
@NP	the vessel walls	11793
@NP	diapedesis of immunocytes infiltrating the entire transplant mass	11822
@NP	diapedesis	11822
@NP	immunocytes infiltrating the entire transplant mass	11836
@NP	immunocytes	11836
@NP	the entire transplant mass	11861
@NP	Thirty-eight rats -LRB- Groups 2 -- 5 -RRB-	11889
@NP	Thirty-eight rats	11889
@NP	Groups 2 -- 5	11908
@NP	Groups 2	11908
@NP	5	11917
@NP	DFR	11936
@NP	the basis	11943
@NP	50 trials	11961
@NP	the DFR	11971
@NP	the two sides	11997
@NP	maximum imbalance 35/15	12012
@NP	maximum imbalance	12012
@NP	35/15	12030
@NP	Unilateral C1/2 CST lesions	12038
@NP	DFR	12082
@NP	3 days	12115
@NP	operation	12128
@NP	Group 2	12139
@NP	Rats	12148
@NP	CST	12165
@NP	Lesions -LRB- n = 11 -RRB-	12169
@NP	Lesions	12169
@NP	n	12178
@NP	11	12182
@NP	11 of these rats	12189
@NP	11	12189
@NP	these rats	12195
@NP	DFR	12206
@NP	2 weeks	12235
@NP	These rats	12244
@NP	the histology	12276
@NP	all 11 cases	12308
@NP	the destruction of the CST	12321
@NP	the destruction	12321
@NP	the CST	12340
@NP	The remaining 27 rats -LRB- Groups 3 -- 5 -RRB-	12364
@NP	The remaining 27 rats	12364
@NP	Groups 3 -- 5	12387
@NP	Groups 3	12387
@NP	5	12396
@NP	complete loss of DFR	12406
@NP	complete loss	12406
@NP	DFR	12423
@NP	8 weeks	12430
@NP	operation	12444
@NP	Group 3	12455
@NP	Rats	12464
@NP	Long-Term Persistence	12480
@NP	Loss of DFR -LRB- n = 8 -RRB-	12505
@NP	Loss	12505
@NP	DFR -LRB- n = 8 -RRB-	12513
@NP	DFR	12513
@NP	n	12518
@NP	8	12522
@NP	the eight rats of this group	12528
@NP	the eight rats	12528
@NP	this group	12546
@NP	DFR testing	12557
@NP	two to three times	12583
@NP	a week	12602
@NP	10 months -LRB- n = 3 -RRB- or 12 months -LRB- n = 5 -RRB-	12613
@NP	10 months -LRB- n = 3 -RRB-	12613
@NP	n	12624
@NP	3	12628
@NP	12 months -LRB- n = 5 -RRB-	12634
@NP	n	12645
@NP	5	12649
@NP	no time	12656
@NP	there	12668
@NP	any spontaneous recovery of DFR on the lesioned side in any of these eight rats	12674
@NP	any spontaneous recovery	12674
@NP	DFR on the lesioned side in any of these eight rats	12702
@NP	DFR	12702
@NP	the lesioned side in any of these eight rats	12709
@NP	the lesioned side	12709
@NP	any of these eight rats	12730
@NP	any	12730
@NP	these eight rats	12737
@NP	Even at the longer survivals none of the eight rats	12755
@NP	Even at the longer survivals none	12755
@NP	the longer survivals	12763
@NP	the eight rats	12792
@NP	any diminution of DFR	12814
@NP	any diminution	12814
@NP	DFR	12832
@NP	the unlesioned side	12839
@NP	Immunostaining	12860
@NP	all these rats	12890
@NP	complete destruction of the CST	12909
@NP	complete destruction	12909
@NP	the CST	12933
@NP	partial destruction of the adjacent gray matter	12946
@NP	partial destruction	12946
@NP	the adjacent gray matter	12969
@NP	two cases spreading into part of the ventral column	13001
@NP	two cases	13001
@NP	part of the ventral column	13026
@NP	part	13026
@NP	the ventral column	13034
@NP	Immunostaining	13054
@NP	astrocytes -LRB- GFAP -RRB- and axons -LRB- neurofilament , NF -RRB-	13073
@NP	astrocytes	13073
@NP	GFAP	13085
@NP	axons	13095
@NP	neurofilament , NF	13102
@NP	neurofilament	13102
@NP	NF	13117
@NP	the lesion center	13133
@NP	any trace of NF staining	13176
@NP	any trace	13176
@NP	NF staining	13189
@NP	the NF + axons of the surrounding spinal tissue by a thick layer of scarred	13236
@NP	the NF	13236
@NP	axons of the surrounding spinal tissue by a thick layer of scarred	13244
@NP	axons	13244
@NP	the surrounding spinal tissue by a thick layer of scarred	13253
@NP	the surrounding spinal tissue	13253
@NP	a thick layer of scarred	13286
@NP	a thick layer	13286
@NP	scarred	13303
@NP	GFAP + astrocytes -LRB- Fig. 1E -RRB-	13311
@NP	GFAP + astrocytes	13311
@NP	Fig. 1E	13329
@NP	The remaining 19 rats with no DFR at 8 weeks after lesion	13339
@NP	The remaining 19 rats	13339
@NP	no DFR at 8 weeks after lesion	13366
@NP	no DFR	13366
@NP	8 weeks after lesion	13376
@NP	8 weeks	13376
@NP	lesion	13390
@NP	mouse OEC/ONF mixtures	13406
@NP	the lesion site	13447
@NP	immunoprotection	13475
@NP	daily cyclosporine -LRB- Groups 4 and 5 -RRB-	13495
@NP	daily cyclosporine	13495
@NP	Groups 4 and 5	13515
@NP	Groups 4	13515
@NP	5	13528
@NP	DFR testing	13532
@NP	3 days	13556
@NP	the transplants	13579
@NP	two to three times a week	13611
@NP	two to three times	13611
@NP	a week	13630
@NP	Group 4	13638
@NP	Rats	13647
@NP	Grafts	13657
@NP	DFR Six	13683
@NP	these cyclosporine-treated rats	13694
@NP	DFR	13735
@NP	5 weeks	13762
@NP	Immunohistochemistry	13787
@NP	all six	13820
@NP	complete destruction of the CST	13832
@NP	complete destruction	13832
@NP	the CST	13856
@NP	partial destruction of the adjacent gray matter	13868
@NP	partial destruction	13868
@NP	the adjacent gray matter	13891
@NP	no transplanted cells and no NF staining	13921
@NP	no transplanted cells	13921
@NP	no NF staining	13947
@NP	the CST lesion center , which was walled off by a heavy GFAP + astrocytic scar	13978
@NP	the CST lesion center	13978
@NP	a heavy GFAP + astrocytic scar	14025
@NP	a heavy GFAP	14025
@NP	astrocytic scar	14039
@NP	GFP labeling	14056
@NP	cyclosporine treatment	14087
@NP	the xenografted mouse cells	14110
@NP	compact masses	14165
@NP	the rostrocaudal axis	14196
@NP	the host spinal cord -LRB- as in the short-term animals of Group 1 -RRB-	14221
@NP	the host spinal cord	14221
@NP	the short-term animals of Group 1	14249
@NP	the short-term animals	14249
@NP	Group 1	14275
@NP	These six transplants	14285
@NP	the scar walling	14328
@NP	the CST lesion area	14349
@NP	a position to bridge the lesion	14395
@NP	the lesion	14416
@NP	Two transplants	14428
@NP	the ascending dorsal column above the CST	14460
@NP	the ascending dorsal column	14460
@NP	the CST	14494
@NP	one	14503
@NP	the ventral spinal cord	14514
@NP	three	14543
@NP	the gray matter	14557
@NP	the CST -LRB- Fig. 1D -RRB-	14585
@NP	the CST	14585
@NP	Fig. 1D	14594
@NP	These transplants	14604
@NP	the ingrowth of local NF + axons from the surrounding area	14634
@NP	the ingrowth of local NF	14634
@NP	the ingrowth	14634
@NP	local NF	14650
@NP	axons from the surrounding area	14660
@NP	axons	14660
@NP	the surrounding area	14671
@NP	Group 5	14693
@NP	Rats	14702
@NP	Return	14712
@NP	DFR -LRB- n = 13 -RRB-	14722
@NP	DFR	14722
@NP	n	14727
@NP	13	14731
@NP	Mouse OEC/ONF Xenografts	14740
@NP	Cyclosporine	14788
@NP	Later Withdrawn	14812
@NP	13 rats	14831
@NP	the cyclosporine-protected mouse OEC/ONF transplants	14839
@NP	DFR	14905
@NP	2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14916
@NP	2 weeks -LRB- n = 11 -RRB-	14916
@NP	n	14925
@NP	11	14929
@NP	3 weeks -LRB- n = 2 -RRB-	14937
@NP	n	14946
@NP	2	14950
@NP	DFR	14959
@NP	cyclosporine and DFR testing	14987
@NP	a further 10 days	15035
@NP	cyclosporine administration	15069
@NP	testing	15116
@NP	8 weeks	15140
@NP	the time of transplantation	15154
@NP	the time	15154
@NP	transplantation	15166
@NP	all 13 rats	15186
@NP	DFR	15198
@NP	5	15216
@NP	6 weeks	15218
@NP	withdrawal of cyclosporine	15232
@NP	withdrawal	15232
@NP	cyclosporine	15246
@NP	a continuous increase -LRB- Fig. 2 -RRB-	15268
@NP	a continuous increase	15268
@NP	Fig. 2	15291
@NP	The histology	15300
@NP	all the spinal cords in this group	15326
@NP	all the spinal cords	15326
@NP	this group	15350
@NP	complete destruction of CST and partial destruction of the adjacent gray matter	15365
@NP	complete destruction of CST	15365
@NP	complete destruction	15365
@NP	CST	15389
@NP	partial destruction of the adjacent gray matter	15397
@NP	partial destruction	15397
@NP	the adjacent gray matter	15420
@NP	Groups 3 and 4	15451
@NP	the rats of Group 1 -LRB- Fig. 1C -RRB- , at 3 weeks after transplantation	15473
@NP	the rats of Group 1 -LRB- Fig. 1C -RRB-	15473
@NP	the rats	15473
@NP	Group 1	15485
@NP	Fig. 1C	15494
@NP	3 weeks	15507
@NP	transplantation	15521
@NP	none of the xenografted cells	15538
@NP	none	15538
@NP	the xenografted cells	15546
@NP	the	15546
@NP	cells	15562
@NP	double immunostaining of GFAP/NF	15591
@NP	double immunostaining	15591
@NP	GFAP/NF	15616
@NP	every case	15639
@NP	NF + axons	15650
@NP	NF	15650
@NP	axons	15654
@NP	the lesion center -LRB- Fig. 1G -- J -RRB-	15681
@NP	the lesion center	15681
@NP	Fig. 1G -- J	15700
@NP	Fig. 1G	15700
@NP	J	15708
@NP	there	15724
@NP	317.14 ± 35.62 NF	15735
@NP	317.14 ±	15735
@NP	35.62 NF	15744
@NP	fibers	15754
@NP	section	15765
@NP	the n	15776
@NP	= 7 spinal cords	15782
@NP	cross section	15806
@NP	this	15821
@NP	the estimate	15852
@NP	320 regenerating axons in our previous rat-to-rat OEC transplants	15868
@NP	320 regenerating axons	15868
@NP	our previous rat-to-rat OEC transplants	15894
@NP	complete CST lesions -LRB- 12 -RRB-	15939
@NP	complete CST lesions	15939
@NP	12	15961
@NP	The GFAP + scar tissue	15967
@NP	The GFAP	15967
@NP	scar tissue	15977
@NP	the cases	16012
@NP	lesion alone -LRB- Group 3 -RRB-	16027
@NP	lesion alone	16027
@NP	Group 3	16041
@NP	some astrocytes	16056
@NP	fine processes	16082
@NP	the margins of the lesion	16102
@NP	the margins	16102
@NP	the lesion	16117
@NP	DISCUSSION Olfactory ensheathing cells	16130
@NP	the olfactory nerves	16179
@NP	their origin in the olfactory mucosa	16205
@NP	their origin	16205
@NP	the olfactory mucosa	16221
@NP	all the way through the cribriform plate to their intracranial termination	16242
@NP	all the way	16242
@NP	the cribriform plate to their intracranial termination	16262
@NP	the cribriform plate	16262
@NP	their intracranial termination	16286
@NP	the olfactory bulb -LRB- 5,23 -RRB-	16320
@NP	the olfactory bulb	16320
@NP	5,23	16340
@NP	Unfortunately , with our current procedures cultures from the mucosal area yield	16347
@NP	Unfortunately , with our current procedures cultures	16347
@NP	our current procedures	16367
@NP	the mucosal area yield	16404
@NP	much smaller proportions of OECs -LRB- 13 -RRB- than those from the bulb	16427
@NP	much smaller proportions	16427
@NP	OECs -LRB- 13 -RRB- than those from the bulb	16455
@NP	OECs -LRB- 13 -RRB-	16455
@NP	OECs	16455
@NP	13	16461
@NP	those from the bulb	16470
@NP	those	16470
@NP	the bulb	16481
@NP	straight comparisons with bulbarsourced cultures	16494
@NP	straight comparisons	16494
@NP	bulbarsourced cultures	16520
@NP	transplantation of mucosal-sourced cultures	16544
@NP	transplantation	16544
@NP	mucosal-sourced cultures	16563
@NP	regeneration of cut axons	16616
@NP	regeneration	16616
@NP	cut axons	16632
@NP	rat CST -LRB- 31 -RRB- , rat dorsal roots -LRB- 9 -RRB-	16645
@NP	rat CST -LRB- 31 -RRB-	16645
@NP	rat CST	16645
@NP	31	16654
@NP	rat dorsal roots -LRB- 9 -RRB-	16659
@NP	rat dorsal roots	16659
@NP	9	16677
@NP	three cases in a human clinical trial -LRB- 25 -RRB-	16688
@NP	three cases	16688
@NP	a human clinical trial -LRB- 25 -RRB-	16703
@NP	a human clinical trial	16703
@NP	25	16727
@NP	expansion	16743
@NP	added growth factors -LRB- 3,6 -RRB-	16756
@NP	added growth factors	16756
@NP	3,6	16778
@NP	It	16784
@NP	this	16808
@NP	the lower proportions of OECs	16822
@NP	the lower proportions	16822
@NP	OECs	16847
@NP	an intrinsic difference between the OECs at these two levels -LRB- 30 -RRB-	16855
@NP	an intrinsic difference	16855
@NP	the OECs at these two levels -LRB- 30 -RRB-	16887
@NP	the OECs	16887
@NP	these two levels -LRB- 30 -RRB-	16899
@NP	these two levels	16899
@NP	30	16917
@NP	the best of our knowledge	16925
@NP	the best	16925
@NP	our knowledge	16937
@NP	the only spinal injured patient who has received autologous bulbar OECs	16951
@NP	the only spinal injured patient	16951
@NP	autologous bulbar OECs	17000
@NP	a pattern of functional recovery highly suggestive of fiber regeneration	17030
@NP	a pattern	17030
@NP	functional recovery highly suggestive	17043
@NP	functional recovery	17043
@NP	fiber regeneration	17084
@NP	the injury site -LRB- 26 -RRB-	17110
@NP	the injury site	17110
@NP	26	17127
@NP	This patient	17132
@NP	a near complete severance	17149
@NP	the midthoracic spinal cord with stump separation of 7	17178
@NP	the midthoracic spinal cord	17178
@NP	stump separation of 7	17211
@NP	stump separation	17211
@NP	7	17231
@NP	8 mm	17233
@NP	his case	17242
@NP	500,000 cells	17251
@NP	culture of a single olfactory bulb	17285
@NP	culture	17285
@NP	a single olfactory bulb	17296
@NP	this number of cells	17324
@NP	this number	17324
@NP	cells	17339
@NP	a bridge	17370
@NP	an injury of this size	17386
@NP	an injury	17386
@NP	this size	17399
@NP	the cells	17410
@NP	the margins of the stumps	17439
@NP	the margins	17439
@NP	the stumps	17454
@NP	peripheral nerve strips	17504
@NP	The mechanics of future clinical cell transplantation	17529
@NP	The mechanics	17529
@NP	future clinical cell transplantation	17546
@NP	larger numbers of cells	17612
@NP	larger numbers	17612
@NP	cells	17630
@NP	Allografts using banks of human bulbar OECs or cell lines	17652
@NP	Allografts	17652
@NP	banks of human bulbar OECs or cell lines	17669
@NP	banks	17669
@NP	human bulbar OECs or cell lines	17678
@NP	human bulbar OECs	17678
@NP	cell lines	17699
@NP	an attractive possibility	17724
@NP	this problem	17761
@NP	the drawbacks	17795
@NP	to source cells from the patient 's own olfactory bulb -LRB- 16 -RRB-	17819
@NP	source	17822
@NP	cells from the patient 's own olfactory bulb -LRB- 16 -RRB-	17829
@NP	cells	17829
@NP	the patient 's own olfactory bulb -LRB- 16 -RRB-	17840
@NP	the patient 's own olfactory bulb	17840
@NP	the patient 's	17840
@NP	16	17874
@NP	Protection of immunoincompatible grafts	17879
@NP	Protection	17879
@NP	immunoincompatible grafts	17893
@NP	all the side effects of requiring the use of immunosuppressive drug regimes	17928
@NP	all the side effects	17928
@NP	the use of immunosuppressive drug regimes	17962
@NP	the use	17962
@NP	immunosuppressive drug regimes	17973
@NP	Such permanent immunosuppression	18005
@NP	situations	18056
@NP	the grafted tissue	18073
@NP	an essential function	18118
@NP	heart , kidney , or pancreatic insulin-secreting cells	18144
@NP	heart	18144
@NP	kidney	18151
@NP	pancreatic insulin-secreting cells	18162
@NP	the recovery of function in the rat CST lesion model	18208
@NP	the recovery	18208
@NP	function in the rat CST lesion model	18224
@NP	function	18224
@NP	the rat CST lesion model	18236
@NP	new fiber connections being formed by the host axons	18272
@NP	new fiber connections	18272
@NP	the host axons	18310
@NP	this recovery	18335
@NP	the transplanted OECs	18364
@NP	it	18387
@NP	the OECs	18411
@NP	the period of providing a bridge for fiber regeneration	18446
@NP	the period	18446
@NP	a bridge for fiber regeneration	18470
@NP	a bridge	18470
@NP	fiber regeneration	18483
@NP	this	18514
@NP	we	18519
@NP	a mouse	18536
@NP	rat xenograft paradigm	18547
@NP	We	18571
@NP	12,32	18583
@NP	total unilateral destruction of the dorsal CST	18601
@NP	total unilateral destruction	18601
@NP	the dorsal CST	18633
@NP	the adjacent medial gray matter at the C1/2 level	18652
@NP	the adjacent medial gray matter	18652
@NP	the C1/2 level	18687
@NP	there	18702
@NP	no return of DFR for up to 12 months -LSB- cf.	18712
@NP	no return	18712
@NP	DFR for up to 12 months	18725
@NP	DFR	18725
@NP	up to 12 months	18733
@NP	e.g. , -LRB- 2,20 -RRB-	18755
@NP	e.g.	18755
@NP	2,20	18762
@NP	The present series	18770
@NP	the transplants	18815
@NP	a bridge across the lesion area	18836
@NP	a bridge	18836
@NP	the lesion area	18852
@NP	there	18868
@NP	no return of function	18877
@NP	no return	18877
@NP	function	18890
@NP	all 13 rats with CST lesions	18903
@NP	all 13 rats	18903
@NP	CST lesions	18920
@NP	loss of DFR	18943
@NP	loss	18943
@NP	DFR	18951
@NP	the transplantation of immunoprotected mouse OEC/ONF xenografts	18955
@NP	the transplantation	18955
@NP	immunoprotected mouse OEC/ONF xenografts	18978
@NP	recovery of DFR	19028
@NP	recovery	19028
@NP	DFR	19040
@NP	This	19045
@NP	a number	19059
@NP	previous studies	19071
@NP	reparative OEC signaling mechanisms	19101
@NP	widely different species -LRB- 10,11,18,19,29 -RRB-	19158
@NP	widely different species	19158
@NP	10,11,18,19,29	19184
@NP	all these rats	19204
@NP	the restored function	19219
@NP	the grafted cells	19262
@NP	an immune attack following removal of the immunosuppressive regime	19312
@NP	an immune attack	19312
@NP	removal of the immunosuppressive regime	19339
@NP	removal	19339
@NP	the immunosuppressive regime	19350
@NP	the OECs	19391
@NP	function	19414
@NP	their continued presence	19424
@NP	the function	19469
@NP	the intimacy	19508
@NP	the association	19524
@NP	the transplanted OECs -LRB- 14 -RRB- and the regenerating fibers , the rejection	19548
@NP	the transplanted OECs -LRB- 14 -RRB-	19548
@NP	the transplanted OECs	19548
@NP	14	19571
@NP	the regenerating fibers , the rejection	19579
@NP	the regenerating fibers	19579
@NP	the rejection	19604
@NP	mechanism	19618
@NP	such precision	19638
@NP	a functionally effective number of regenerating CST fibers	19658
@NP	a functionally effective number	19658
@NP	regenerating CST fibers	19693
@NP	an immune attack completely destroying the xenografted mouse OECs	19726
@NP	an immune attack	19726
@NP	the xenografted mouse OECs	19765
@NP	Histological analysis	19793
@NP	the return of function	19826
@NP	the return	19826
@NP	function	19840
@NP	the 2 -- 300 fibers present in the lesion center	19870
@NP	the 2 -- 300 fibers present	19870
@NP	the 2	19870
@NP	300 fibers	19876
@NP	the lesion center	19898
@NP	rejection of the xenografted mouse cells	19922
@NP	rejection	19922
@NP	the xenografted mouse cells	19935
@NP	This	19964
@NP	the number of CST fibers , which restored DFR in a previous study -LRB- 12 -RRB-	19986
@NP	the number	19986
@NP	CST fibers , which restored DFR in a previous study -LRB- 12 -RRB-	20000
@NP	CST fibers	20000
@NP	DFR in a previous study -LRB- 12 -RRB-	20027
@NP	DFR	20027
@NP	a previous study -LRB- 12 -RRB-	20034
@NP	a previous study	20034
@NP	12	20052
@NP	a similar study -LRB- 1 -RRB-	20060
@NP	a similar study	20060
@NP	1	20077
@NP	researchers	20080
@NP	rat Schwann cells	20104
@NP	mouse peripheral nerve under immunosuppressive conditions	20139
@NP	mouse peripheral nerve	20139
@NP	immunosuppressive conditions	20168
@NP	the host fibers	20208
@NP	the host fibers	20233
@NP	subsequent rejection	20258
@NP	the foreign myelinating cells -LRB- Aguayo personal communication -RRB-	20282
@NP	the foreign myelinating cells	20282
@NP	Aguayo personal communication	20313
@NP	Aguayo	20313
@NP	personal communication	20320
@NP	The importance of our present finding	20345
@NP	The importance	20345
@NP	our present finding	20363
@NP	it	20391
@NP	the possibility of using transient immunoprotection of allografted cells	20400
@NP	the possibility	20400
@NP	transient immunoprotection of allografted cells	20425
@NP	transient immunoprotection	20425
@NP	allografted cells	20455
@NP	the surgical repair	20478
@NP	large human spinal cord injuries	20501
@NP	the ability	20534
@NP	allografted cells or cell lines	20553
@NP	an approach	20599
@NP	round	20622
@NP	the numerical restriction of autologously sourced cells	20628
@NP	the numerical restriction	20628
@NP	cells	20678
@VP	is one of the most promising strategies for repair of human spinal cord injuries	190
@VP	cultured from biopsies of the olfactory bulb	380
@VP	mediate axonal regeneration and remyelination	425
@VP	restore lost functions in spinal cord injuries	475
@VP	encountered in human patients	617
@VP	can be obtained from a patient 's own olfactory bulb	673
@VP	be obtained from a patient 's own olfactory bulb	677
@VP	obtained from a patient 's own olfactory bulb	680
@VP	becomes a serious limiting factor	725
@VP	limiting factor	743
@VP	requires invasive surgery and risks unilateral anosmia	802
@VP	immunoprotected by daily cyclosporine	931
@VP	had been established for 10 days	1092
@VP	been established for 10 days	1096
@VP	established for 10 days	1101
@VP	was withdrawn	1139
@VP	withdrawn	1143
@VP	continued to increase directed forepaw reaching	1178
@VP	to increase directed forepaw reaching	1188
@VP	increase directed forepaw reaching	1191
@VP	directed forepaw reaching	1200
@VP	reaching	1217
@VP	were present in the lesion	1300
@VP	had been totally rejected	1355
@VP	been totally rejected	1359
@VP	totally rejected	1364
@VP	once grafted cells	1400
@VP	is no longer necessary for maintaining the restored function	1511
@VP	maintaining the restored function	1538
@VP	would avoid the need for removing a patient 's olfactory bulb	1778
@VP	avoid the need for removing a patient 's olfactory bulb	1784
@VP	removing a patient 's olfactory bulb	1803
@VP	completely destroying the adult rat corticospinal tract	2127
@VP	partial adjacent medial gray matter unilaterally at the C1/2 level	2193
@VP	Following this lesion	2261
@VP	directed forepaw reaching -LRB- DFR -RRB- on the lesion side was totally absent	2284
@VP	reaching -LRB- DFR -RRB- on the lesion side	2301
@VP	was totally absent	2335
@VP	cultured adult bulbar OECs and olfactory nerve fibroblasts -LRB- ONFs -RRB-	2423
@VP	restored DFR after around 10 days -LRB- 12 -RRB-	2489
@VP	to obtain more cells and to avoid the problems of autograft biopsy	2716
@VP	to obtain more cells	2716
@VP	obtain more cells	2719
@VP	to avoid the problems of autograft biopsy	2741
@VP	avoid the problems of autograft biopsy	2744
@VP	would be to build up a bank of allogeneic cells or cell lines -LRB- 16 -RRB-	2783
@VP	be to build up a bank of allogeneic cells or cell lines -LRB- 16 -RRB-	2789
@VP	to build up a bank of allogeneic cells or cell lines -LRB- 16 -RRB-	2792
@VP	build up a bank of allogeneic cells or cell lines -LRB- 16 -RRB-	2795
@VP	would therefore have to cross an immune barrier	2873
@VP	have to cross an immune barrier	2889
@VP	to cross an immune barrier	2894
@VP	cross an immune barrier	2897
@VP	immunoprotected with cyclosporine	3006
@VP	carries many disadvantages	3160
@VP	restored under transient immunosuppression	3282
@VP	would remain after the immunosuppressive regime was discontinued	3325
@VP	remain after the immunosuppressive regime was discontinued	3331
@VP	was discontinued	3373
@VP	discontinued	3377
@VP	bred , London , UK , body weight 200 -- 220 g	3516
@VP	bred	3516
@VP	were used	3557
@VP	used	3562
@VP	received mouse OEC / ONF xenografts without immunosuppression	3600
@VP	had CST lesions and were tested for DFR	3783
@VP	had CST lesions	3783
@VP	were tested for DFR	3803
@VP	tested for DFR	3808
@VP	had not been abolished	3860
@VP	been abolished	3868
@VP	abolished	3873
@VP	were sacrificed for histology	3893
@VP	sacrificed for histology	3898
@VP	was abolished	3959
@VP	abolished	3963
@VP	to check that DFR would not return	4030
@VP	check that DFR would not return	4033
@VP	would not return	4048
@VP	return	4058
@VP	received mouse OEC/ONF xenografts at 8 weeks after the CST lesions	4127
@VP	was applied immediately and continued afterward with daily injections	4223
@VP	was applied immediately	4223
@VP	applied immediately	4227
@VP	continued afterward with daily injections	4251
@VP	showed no return of DFR at 5 weeks after receiving mouse OEC transplants	4321
@VP	receiving mouse OEC transplants	4362
@VP	were terminated for histology	4400
@VP	terminated for histology	4405
@VP	had returned after receiving mouse OEC transplants	4478
@VP	returned after receiving mouse OEC transplants	4482
@VP	receiving mouse OEC transplants	4497
@VP	was continued for a further 10 days after the day when DFR had returned	4553
@VP	continued for a further 10 days after the day when DFR had returned	4557
@VP	had returned	4612
@VP	returned	4616
@VP	was stopped	4655
@VP	stopped	4659
@VP	receiving the transplants	4744
@VP	Reaching -LRB- DFR -RRB- and Microsurgery All animals	4788
@VP	was carried out as previously described -LRB- 12 -RRB-	5081
@VP	carried out as previously described -LRB- 12 -RRB-	5085
@VP	described -LRB- 12 -RRB-	5111
@VP	used both right and left paws -LRB- more than 15 times each -RRB-	5297
@VP	used both right	5297
@VP	left paws -LRB- more than 15 times each -RRB-	5317
@VP	were selected for making the CST lesions	5353
@VP	selected for making the CST lesions	5358
@VP	making the CST lesions	5371
@VP	using an electrode -LRB- LCE ; Cosman Medical Inc. , Burlington , MA , USA -RRB-	5568
@VP	operating at 10 V for 1 min as previously described -LRB- 32 -RRB-	5793
@VP	described	5835
@VP	was resumed 3 days after the lesion , two to three times a week	5876
@VP	resumed 3 days after the lesion , two to three times a week	5880
@VP	showed complete absence of DFR for 8 weeks	5950
@VP	were selected to receive mouse OEC transplants -LRB- Groups 4 and 5 -RRB-	5993
@VP	selected to receive mouse OEC transplants -LRB- Groups 4 and 5 -RRB-	5998
@VP	to receive mouse OEC transplants -LRB- Groups 4 and 5 -RRB-	6007
@VP	receive mouse OEC transplants -LRB- Groups 4 and 5 -RRB-	6010
@VP	were maintained up to 12 months as a long-term control -LRB- Group 3 -RRB-	6098
@VP	maintained up to 12 months as a long-term control -LRB- Group 3 -RRB-	6103
@VP	plated on to 35-mm Nunc ™ dishes	6443
@VP	coated with poly-d-lysine -LRB- Sigma - Aldrich , Dorset , UK -RRB-	6524
@VP	were maintained for 15	6590
@VP	maintained for 15	6595
@VP	were transfected with a GFP gene harboring lentiviral construct	7098
@VP	transfected with a GFP gene harboring lentiviral construct	7103
@VP	harboring lentiviral construct	7131
@VP	was made up at a final concentration of 25 × 106/ml in DMEM-F12 without FCS	7193
@VP	made up at a final concentration of 25 × 106/ml in DMEM-F12 without FCS	7197
@VP	was delivered intraperitoneally -LRB- IP -RRB-	7641
@VP	delivered intraperitoneally -LRB- IP -RRB-	7645
@VP	repeated daily	7746
@VP	was restarted 3 days after the transplantation	7774
@VP	restarted 3 days after the transplantation	7778
@VP	maintained two to three times weekly	7825
@VP	see Keyvan-Fouladi	8015
@VP	was used for cell counterstaining	8620
@VP	used for cell counterstaining	8624
@VP	captured using a Leica confocal microscope TCS SP -LRB- Milton Keynes , UK -RRB-	8679
@VP	using a Leica confocal microscope TCS SP -LRB- Milton Keynes , UK -RRB-	8688
@VP	Group 1	8810
@VP	Failed restoration of DFR , the OECs not located in the lesion	9016
@VP	Group 3	9254
@VP	showing no recovery of DFR	9290
@VP	xenografted cells	9520
@VP	cross sections	9728
@VP	Maintained function after rejection of xenografts	9823
@VP	ordinate	9915
@VP	mean ± SD	9925
@VP	return of DFR after mouse OEC/ONF xenografts -LRB- TR -RRB-	10067
@VP	protected by daily cyclosporine	10127
@VP	biopsied mouse olfactory bulbs yielded a mixture of 60	10441
@VP	yielded a mixture of 60	10472
@VP	flattened , short-processed multipolar ONFs	10561
@VP	were carried out in the other groups	10703
@VP	carried out in the other groups	10708
@VP	identified by the GFP labeling	10775
@VP	survived well	10807
@VP	were elongated to around 100 μm	11004
@VP	elongated to around 100 μm	11009
@VP	were orientated in parallel to the host CST -LRB- Fig. 1A -RRB-	11097
@VP	orientated in parallel to the host CST -LRB- Fig. 1A -RRB-	11102
@VP	were reduced to around 30 % of those seen at 4 days	11195
@VP	reduced to around 30 % of those seen at 4 days	11200
@VP	seen at 4 days	11231
@VP	elongated longitudinal pattern	11284
@VP	appeared to be breaking up into irregular blob-like shapes -LRB- Fig. 1B -RRB-	11319
@VP	to be breaking up into irregular blob-like shapes -LRB- Fig. 1B -RRB-	11328
@VP	be breaking up into irregular blob-like shapes -LRB- Fig. 1B -RRB-	11331
@VP	breaking up into irregular blob-like shapes -LRB- Fig. 1B -RRB-	11334
@VP	suggesting an influx of host immunocytes and perivascular cuffing	11455
@VP	retained the hypercellularity and the hollow vascular areas -LRB- Fig. 1C -RRB-	11621
@VP	intimately associated with the vessel walls	11766
@VP	suggesting diapedesis of immunocytes infiltrating the entire transplant mass	11811
@VP	infiltrating the entire transplant mass	11848
@VP	was comparable on the two sides -LRB- maximum imbalance 35/15 -RRB-	11979
@VP	were performed	12066
@VP	performed	12071
@VP	was tested twice weekly from 3 days after operation	12086
@VP	tested twice weekly from 3 days after operation	12090
@VP	Failed CST Lesions -LRB- n = 11 -RRB- In 11 of these rats	12158
@VP	started to return within 2 weeks	12210
@VP	to return within 2 weeks	12218
@VP	return within 2 weeks	12221
@VP	were sacrificed	12255
@VP	sacrificed	12260
@VP	confirmed that in all 11 cases the destruction of the CST was incomplete	12290
@VP	was incomplete	12348
@VP	showed complete loss of DFR at 8 weeks after operation	12399
@VP	was there	12664
@VP	showed any diminution of DFR on the unlesioned side	12807
@VP	spreading into part of the ventral column	13011
@VP	was completely devoid of any trace of NF staining	13151
@VP	followed by immunoprotection by daily cyclosporine -LRB- Groups 4 and 5 -RRB-	13463
@VP	was resumed 3 days after receiving the transplants	13544
@VP	resumed 3 days after receiving the transplants	13548
@VP	receiving the transplants	13569
@VP	carried out two to three times a week	13599
@VP	had not returned after 5 weeks were terminated	13739
@VP	returned after 5 weeks were terminated	13747
@VP	were terminated	13770
@VP	terminated	13775
@VP	was walled off by a heavy GFAP + astrocytic scar	14007
@VP	walled off by a heavy GFAP + astrocytic scar	14011
@VP	were located outside the scar walling off the CST lesion area	14307
@VP	were therefore not in a position to bridge the lesion	14373
@VP	to bridge the lesion	14406
@VP	bridge the lesion	14409
@VP	were located in the ascending dorsal column above the CST	14444
@VP	located in the ascending dorsal column above the CST	14449
@VP	was in the ventral spinal cord	14507
@VP	were in the gray matter adjacent to the CST -LRB- Fig. 1D -RRB-	14549
@VP	had induced the ingrowth of local NF + axons from the surrounding area	14622
@VP	induced the ingrowth of local NF + axons from the surrounding area	14626
@VP	had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14892
@VP	restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14896
@VP	had been reestablished	14963
@VP	been reestablished	14967
@VP	reestablished	14972
@VP	was terminated	15097
@VP	terminated	15101
@VP	continued until 8 weeks after the time of transplantation	15124
@VP	showing a continuous increase -LRB- Fig. 2 -RRB-	15260
@VP	xenografted cells	15550
@VP	had survived	15568
@VP	survived	15572
@VP	were seen traversing the lesion center -LRB- Fig. 1G -- J -RRB-	15660
@VP	seen traversing the lesion center -LRB- Fig. 1G -- J -RRB-	15665
@VP	traversing the lesion center -LRB- Fig. 1G -- J -RRB-	15670
@VP	extending fine processes into the margins of the lesion	16072
@VP	has received autologous bulbar OECs	16987
@VP	received autologous bulbar OECs	16991
@VP	were available from culture of a single olfactory bulb	17265
@VP	was insufficient to form a bridge across an injury of this size	17345
@VP	to form a bridge across an injury of this size	17362
@VP	form a bridge across an injury of this size	17365
@VP	were injected into the margins of the stumps	17420
@VP	injected into the margins of the stumps	17425
@VP	bridging	17470
@VP	was provided by grafting peripheral nerve strips	17479
@VP	provided by grafting peripheral nerve strips	17483
@VP	grafting peripheral nerve strips	17495
@VP	would be greatly enhanced if larger numbers of cells were available	17583
@VP	be greatly enhanced if larger numbers of cells were available	17589
@VP	greatly enhanced if larger numbers of cells were available	17592
@VP	were available	17636
@VP	using banks of human bulbar OECs or cell lines	17663
@VP	would provide an attractive possibility to address this problem	17710
@VP	provide an attractive possibility to address this problem	17716
@VP	to address this problem	17750
@VP	address this problem	17753
@VP	having to source cells from the patient 's own olfactory bulb -LRB- 16 -RRB-	17812
@VP	requiring the use of immunosuppressive drug regimes	17952
@VP	depends on new fiber connections being formed by the host axons	18261
@VP	being formed by the host axons	18294
@VP	formed by the host axons	18300
@VP	is mediated by the transplanted OECs	18349
@VP	mediated by the transplanted OECs	18352
@VP	to be present beyond the period of providing a bridge for fiber regeneration	18425
@VP	be present beyond the period of providing a bridge for fiber regeneration	18428
@VP	providing a bridge for fiber regeneration	18460
@VP	To examine this	18503
@VP	examine this	18506
@VP	here describe a mouse to rat xenograft paradigm	18522
@VP	was no return of DFR for up to 12 months -LSB- cf.	18708
@VP	-LSB- cf.	18749
@VP	cf.	18750
@VP	-RSB-	18767
@VP	form a bridge across the lesion area	18831
@VP	is no return of function	18874
@VP	leading to loss of DFR	18932
@VP	mediated recovery of DFR	19019
@VP	are conserved across widely different species -LRB- 10,11,18,19,29 -RRB-	19137
@VP	conserved across widely different species -LRB- 10,11,18,19,29 -RRB-	19141
@VP	have restored function	19400
@VP	restored function	19405
@VP	is not required for the function to be maintained	19449
@VP	required for the function to be maintained	19456
@VP	to be maintained	19482
@VP	be maintained	19485
@VP	maintained	19488
@VP	survived an immune attack completely destroying the xenografted mouse OECs	19717
@VP	completely destroying the xenografted mouse OECs	19743
@VP	restored DFR in a previous study -LRB- 12 -RRB-	20018
@VP	xenografted into mouse peripheral nerve under immunosuppressive conditions	20122
@VP	myelinated the host fibers	20197
@VP	opens the possibility of using transient immunoprotection of allografted cells	20394
@VP	using transient immunoprotection of allografted cells	20419
@VP	to use allografted cells or cell lines	20546
@VP	use allografted cells or cell lines	20549
@VP	could provide an approach to getting round	20585
@VP	provide an approach to getting round	20591
@VP	getting round	20614
@VP	sourced cells	20670
